Welcome

OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.

DIAGNOSTIC PRODUCTS:

"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.

R&D SERVICES:

OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.

 

Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology
Events
News

10/31/2018

News

SYNLAB y OWL Metabolomics firman un Acuerdo Estratégico para la Comercialización en España del Test OWLiver el único test no invasivo para el diagnóstico de hígado graso
SYNLAB, líder en servicios de diagnóstico médico en el mercado europeo y OWL Metabolomics, compañía biotecnológica pionera en el desarrollo de test no invasivos para el diagnóstico de NAFLD/NASH, anuncian su alianza comercial para la comercialización de OWLiver (único test no invasivo para el diagnóstico de hígado graso no alcohólico (NAFLD) y de esteatopatitis no alcohólica (NASH) que se basa en el análisis lipidómico del suero de los pacientes.
La iniciativa pretende facilitar el acceso al diagnóstico no invasivo de NASH (OWLiver) también en los hospitales españoles privados. En este momento OWL Metabolomics ya cuenta con una amplia red de hospitales públicos en los que ya se puede prescribir el test OWLiver. Con el presente acuerdo se extiende esa posibilidad a la práctica totalidad del medio hospitalario privado a través de la red de SYNLAB.

 

10/31/2018

News

SYNLAB and OWL Metabolomics enter into a Strategic Alliance for the Commercialization in Spain of the OWLiver® Test, the unique non-invasive diagnostic for NAFLD/NASH.
SYNLAB, a leading company in medical diagnostic services in the European Market and OWL Metabolomics, a biotechnology company in the field of Metabolomics with pioneering diagnostics products, announce its strategic alliance for the commercialization of the OWLiver® test, the unique robust and non-invasive blood-based test for the diagnosis of non-alcoholic fatty liver (NAFL) and non-alcoholic steato-hepatitis (NASH) based in the lipidomic analysis.
SYNLAB, a leading company in medical diagnostic services in the European Market and OWL Metabolomics, a biotechnology company in the field of Metabolomics with pioneering diagnostics products, announce its strategic alliance for the commercialization of the OWLiver® test, the unique robust and non-invasive blood-based test for the diagnosis of non-alcoholic fatty liver (NAFL) and non-alcoholic steato-hepatitis (NASH) based in the lipidomic analysis.
This initiative aims to facilitate the access of the NASH non-invasive diagnostic test (OWLiver®) to the Spanish private hospitals and healthcare institutions. At present OWL Metabolomics has introduced this test in a broad network of public hospitals where the test OWLiver® can be already prescribed by physicians. With the present agreement, the availability of the OWLiver® test will be extended practically to the complete healthcare systems in the territory through the SYNLAB laboratory network.

 

07/09/2018

News

CONVOCATORIA DE LA JUNTA GENERAL EXTRAORDINARIA DE SOCIOS DE ONE WAY LIVER, S.L.

 

06/28/2018

News

Knowledge transfer from Basic Liver Research to NASH Drug Therapy Research
Galmed Pharmaceuticals recently announced that their lead NASH drug candidate, Aramchol, had achieved an FDA- regulatory-approvable endpoint demonstrating NASH resolution in the Aramchol Phase 2b, 52-week ARREST trial. Aramchol is a conjugate of cholic acid and arachidic acid, a first-in-class member of a novel family of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). These positive results mean that this new drug is on track for Phase III initiation and further clinical evaluation of its efficacy in NASH.

 

06/12/2018

News

Newly-published studies further underscore the value of novel, non-invasive testing in patients with NASH
As part of the First International NASH Day, OWL Metabolomics proudly announces the very recent publication of 3 scientific papers that specifically evaluate the utility of metabolomics-based laboratory testing in a variety of non-alcoholic steatohepatitis (NASH) clinical applications.

 

04/25/2018

News

CONVOCATORIA DE LA JUNTA GENERAL ORDINARIA Y EXTRAORDINARIA DE SOCIOS DE ONE WAY LIVER, S.L. 14 DE MAYO DE 2018
Por acuerdo del Consejo de Administración de la compañía, se convoca a los señores socios a la Junta General ordinaria y extraordinaria de Socios que tendrá lugar en el domicilio social, en Derio (Bizkaia), Parque Tecnológico, Edificio nº 502, planta 0, el día 14 de mayo de 2018 a las 12.30 horas

 

01/11/2018

News

El hospital CIMA Sanitas es el primer hospital privado de Cataluña en utilizar un novedoso test para el diagnóstico no invasivo del hígado graso
12/12/2017

La enfermedad de hígado graso no alcohólico (NAFLD, en inglés) comprende desde la esteatosis (hígado graso) hasta la más grave esteatohepatitis no alcohólica (en inglés, NASH), que puede evolucionar a cirrosis y cáncer hepático. El NAFLD está relacionado con la obesidad y diabetes, afecta al 20-30% de la población y se estima que pasará a ser la principal causa de trasplante hepático en pocos años.

 

OWL is a trading name of
ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone:
+34 94 431 85 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 11/08/2018

With the collaboration of: